Speech Fluency Disorders: A Review of Studies Conducted Over the Past Five Decades (1970-2020)

References (110)

1. 1 Stuttering and the basal ganglia circuits: a critical review of possible relations [DOI]
2. 2 The impact of stuttering on the quality of life in adults who stutter [DOI]
3. 3 Normative Disfluency Data for Early Childhood Stuttering [DOI]
4. 4 Brain anatomy differences in childhood stuttering [DOI]
5. 5 The impact of stuttering on employment opportunities and job performance [DOI]
6. 6 Childhood stuttering [DOI]
7. 7 Stuttering Treatment Research 1970–2005: I. Systematic Review Incorporating Trial Quality Assessment of Behavioral, Cognitive, and Related Approaches [DOI]
8. 8 Direct versus Indirect Treatment for Preschool Children who Stutter: The RESTART Randomized Trial [DOI]
9. 9 Stuttering in relation to anxiety, temperament, and personality: Review and analysis with focus on causality [DOI]
10. 10 Parent perceptions of the impact of stuttering on their preschoolers and themselves [DOI]
11. 11 The Neurobiological Grounding of Persistent Stuttering: from Structure to Function [DOI]
12. 12 Genetic Etiology in Cases of Recovered and Persistent Stuttering in an Unselected, Longitudinal Sample of Young Twins [DOI]
13. 13 Language Abilities of Children Who Stutter: A Meta-Analytical Review [DOI]
14. 14 Stuttering severity and educational attainment [DOI]
15. 15 Genomewide Significant Linkage to Stuttering on Chromosome 12 [DOI]
16. 16 Quality of life in adults who stutter [DOI]
17. 17 Non-verbal sensorimotor timing deficits in children and adolescents who stutter [DOI]
18. 18 Anxiety of children and adolescents who stutter: A review [DOI]
19. 19 Results of a genome‐wide linkage scan for stuttering [DOI]
20. 20 Communicating in the real world: accounts from people who stammer [DOI]
21. 21 Stuttering following acquired brain damage: A review of the literature [DOI]
22. 22 Alleviating stuttering with pharmacological interventions [DOI]
23. 23 Genetic and Environmental Influences on Stuttering and Tics in Japanese Twin Children [DOI]
24. 24 Exploratory Randomized Clinical Study of Pagoclone in Persistent Developmental Stuttering [DOI]
25. 25 Analysis of five cases with neurogenic stuttering following brain injury in the basal ganglia [DOI]
26. 26 Anticipation in stuttering: A theoretical model of the nature of stutter prediction [DOI]
27. 27 The state of the art in non-pharmacological interventions for developmental stuttering. Part 2: qualitative evidence synthesis of views and experiences [DOI]
28. 28 Stuttering: an overview.
29. 29 Acquired stuttering: A note on terminology [DOI]
30. 30 Risperidone for the Treatment of Stuttering [DOI]
31. 31 Prediction of Outcome After Treatment for Stuttering [DOI]
32. 32 Drug-Induced Stuttering [DOI]
33. 33 A longitudinal study of articulation, language, rate, and fluency of 22 preschool children who stutter [DOI]
34. 34 Mood and Substance Use Disorders Among Adults Seeking Speech Treatment for Stuttering [DOI]
35. 35 Sudden onset stuttering in an adult: Neurogenic and psychogenic perspectives [DOI]
36. 36 Addressing generalization and maintenance of stuttering treatment in the schools: a critical look [DOI]
37. 37 Looking at stuttering through the lens of complexity [DOI]
38. 38 “Not Unless It’s a Life or Death Thing”: A Qualitative Study of the Health Care Experiences of Adults Who Stutter [DOI]
39. 39 Disfluent speech in patients with partial epilepsy: Beneficial effect of levetiracetam [DOI]
40. 40 Stuttering after right cerebellar infarction: A case study [DOI]
41. 41 Evaluation of the association between polymorphisms at the DRD2 locus and stuttering [DOI]
42. 42 Revisiting the acquired neurogenic stuttering in the light of developmental stuttering [DOI]
43. 43 Olanzapine for the Treatment of Acquired Neurogenic Stuttering [DOI]
44. 44 Developmental dysfluency: early intervention is key [DOI]
45. 45 Controlled Trial of the Treatment of 36 Stutterers [DOI]
46. 46 Case Report of Aripiprazole for Persistent Developmental Stuttering [DOI]
47. 47 Alprazolam, Citalopram, and Clomipramine for Stuttering [DOI]
48. 48 Acquired stuttering due to recurrent anaplastic astrocytoma [DOI]
49. 49 Neurogenic stuttering in corticobasal ganglionic degeneration: A case report [DOI]
50. 50 Gabapentin for Treating Acquired Neurogenic Stuttering [DOI]
51. 51 The alliance in adult psychotherapy: A meta-analytic synthesis. [DOI]
52. 52 The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration [DOI]
53. 53 Social anxiety disorder and stuttering: Current status and future directions [DOI]
54. 54 Screening for Speech and Language Delay in Children 5 Years Old and Younger: A Systematic Review [DOI]
55. 55 Trait and social anxiety in adults with chronic stuttering: Conclusions following meta-analysis [DOI]
56. 56 Predicting Stuttering Onset by the Age of 3 Years: A Prospective, Community Cohort Study [DOI]
57. 57 Neural network connectivity differences in children who stutter [DOI]
58. 58 Stuttering: a dynamic motor control disorder [DOI]
59. 59 A Controlled Clinical Trial for Stuttering in Persons Aged 9 to 14 Years [DOI]
60. 60 Stammering and therapy views of people who stammer [DOI]
61. 61 Prevalence of anxiety disorders among children who stutter [DOI]
62. 62 White matter neuroanatomical differences in young children who stutter [DOI]
63. 63 Responses of adults who stutter to the anticipation of stuttering [DOI]
64. 64 Lidcombe Program Webcam Treatment for Early Stuttering: A Randomized Controlled Trial [DOI]
65. 65 Axis I anxiety and mental health disorders among stuttering adolescents [DOI]
66. 66 Association between dopaminergic genes (SLC6A3 and DRD2) and stuttering among Han Chinese [DOI]
67. 67 Transcranial direct current stimulation over left inferior frontal cortex improves speech fluency in adults who stutter [DOI]
68. 68 Genetic and environmental effects on stuttering: A twin study from Finland [DOI]
69. 69 What Causes Stuttering? [DOI]
70. 70 Co-occurring disorders in children who stutter [DOI]
71. 71 New Complexities in the Genetics of Stuttering: Significant Sex-Specific Linkage Signals [DOI]
72. 72 Intensive Stuttering Modification Therapy [DOI]
73. 73 Genetic studies of stuttering in a founder population [DOI]
74. 74 Subjective Screening of Stuttering severity, locus of control and avoidance: research edition [DOI]
75. 75 Stuttering: Clinical and research update.
76. 76 When will a stuttering moment occur? The determining role of speech motor preparation [DOI]
77. 77 Functional neural circuits that underlie developmental stuttering [DOI]
78. 78 Stuttering treatment and brain research in adults: A still unfolding relationship [DOI]
79. 79 The pharmacology of stuttering: a critical review [DOI]
80. 80 The Prediction and Prevention of Relapse in Stuttering [DOI]
81. 81 Treatment with medications affecting dopaminergic and serotonergic mechanisms: Effects on fluency and anxiety in persons who stutter [DOI]
82. 82 Stuttering and Stimulants [DOI]
83. 83 Assisted and unassisted recession of functional anomalies associated with dysprosody in adults who stutter [DOI]
84. 84 Stuttering Due To Ischemic Stroke [DOI]
85. 85 Tartamudez neurógena: revisión de la bibliografía [DOI]
86. 86 A double-blind comparison of clomipramine and desipramine in the treatment of developmental stuttering.
87. 87 Differential Diagnosis of Stuttering for Forensic Purposes [DOI]
88. 88 Asenapine for the Treatment of Stuttering: An Analysis of Three Cases [DOI]
89. 89 Ziprasidone for the Treatment of Stuttering [DOI]
90. 90 The effect of haloperidol on stuttering [DOI]
91. 91 Fluency Changes in Persons Who Stutter Following a Double Blind Trial of Clomipramine and Desipramine [DOI]
92. 92 DSM-IV CRITERIA FOR TOURETTE'S [DOI]
93. 93 Stuttering Onset Associated with Streptococcal Infection: A Case Suggesting Stuttering as Pandas [DOI]
94. 94 Crossed apraxia of speech: A case report [DOI]
95. 95 Olanzapine versus haloperidol: which can control stuttering better?
96. 96 Case Report of Aripiprazole in the Treatment of Adolescent Stuttering [DOI]
97. 97 Neurogenic speech sequelae following suicide attempt by hanging: a case report [DOI]
98. 98 Neurogenic stuttering with right hemisphere stroke: A case presentation [DOI]
99. 99 Genetic Aspects Of Idiopathic Speech And Language Disorders [DOI]
100. 100 Deep Brain Stimulation for the Treatment of Obsessive-Compulsive Disorder with Implications for Improvements in Stuttering [DOI]
101. 101 Stuttering as Defined by Adults Who Stutter [DOI]
102. 102 The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis [DOI]
103. 103 Supplementing stuttering treatment with online cognitive behavior therapy: An experimental trial [DOI]
104. 104 Associations between stuttering, comorbid conditions and executive function in children: a population-based study [DOI]
105. 105 Examining the Association between Stuttering and Psychopathic Personality Traits, Nonviolent Crime, and Violent Crime [DOI]
106. 106 Stuttering: Understanding and Treating a Common Disability.
107. 107 Measuring and monitoring emotional changes in children who stutter [DOI]
108. 108 A Case Series on the Effectiveness of Lurasidone in Patients with Stuttering [DOI]
109. 109 Methylphenidate and stuttering [DOI]
110. 110 Ecopipam as a Pharmacologic Treatment of Stuttering [DOI]

Cited by 6

Showing 3 of 6 known citations — external sources report more than can currently be individually listed.

Related research

• The Nature and Complications of Acute Traumatic Cervical Spinal Cord Injury in a University Hospital in Nigeria — shares topic coverage
• Risk Factors Assessment of Zoonotic Anthrax among the People at Risk (PAR) in Selected Areas of Bangladesh — shares topic coverage
• Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
• Systematic Review of Visceral Leishmaniasis in Central Africa — shares topic coverage
• Administration of High-Risk Medication: A Hospital Based Prospective Study — shares topic coverage